Goodwin attorneys recently advised Moderna Therapeutics on its announced $110 million financing round. In total, the company has raised more than $415 million in financings and partnerships since inception, including its landmark option agreement with AstraZeneca earlier this year.
Moderna is the pioneer in messenger RNA Therapeutics™, a new in vivo drug modality that produces human proteins or antibodies inside patient cells, which are in turn active intracellularly or secreted. The company’s platform addresses currently undruggable targets and offers an alternative to existing drug modalities for a wide range of disease conditions. Moderna plans to develop and commercialize its mRNA drugs—initially for rare diseases and oncology—while partnering drug candidates in other therapeutic areas in order to deliver this innovation to patients. Moderna is a privately held company based in Cambridge, Mass.
The Goodwin team advising on the financing was led by partners Kingsley Taft, Stuart Cable and Danielle Lauzon.
More information about Moderna’s financing is available in the company’s press release.